Main Uses of Helicobacter Test Infai

Helicobacter Test Infai is a diagnostic tool used to identify the presence of Helicobacter pylori (H. pylori) in the stomach and the upper part of the small intestine. It is primarily utilized in adults and adolescents when there is a clinical suspicion of an infection or related gastric conditions.

Detection of H. pylori Infection

The test is designed to provide a non-invasive way to determine if a patient is currently harboring the H. pylori bacterium. This organism is a common cause of gastritis (inflammation of the stomach lining) and is a significant factor in the development of peptic ulcers.

Monitoring Treatment Success

Beyond initial diagnosis, the test is frequently used to verify whether a prescribed course of treatment, such as a combination of antibiotics and acid-reducing medications, has successfully eradicated the bacteria. Post-treatment testing helps healthcare providers confirm that the infection is no longer present.

Benefits of the Test

Non-Invasive Procedure

A primary benefit of this test is that it does not require an endoscopy or the collection of tissue samples (biopsies). It relies on the analysis of breath samples, making it a more comfortable option for patients compared to invasive diagnostic methods.

Accuracy and Reliability

The test is based on the urea breath test principle, which is recognized for its high sensitivity and specificity. This means it is highly effective at correctly identifying both the presence and the absence of the infection, reducing the likelihood of false results.

Immediate Physiological Insight

Because the test measures the activity of the urease enzyme produced by the bacteria, it reflects the current status of the infection. This allows for a real-time assessment of whether the bacteria are active within the gastrointestinal tract at the time of testing.

Regulatory References

1. NIH MedlinePlus overview

The Helicobacter Test Infai is a diagnostic breath test used to detect an active Helicobacter pylori (H. pylori) infection in the stomach and duodenum.

Who Can Use the Test

The test is typically indicated for a broad range of patients suspected of having an H. pylori infection, or to verify the success of eradication treatment.

Patient Group	Indication
Adults and Adolescents (12+ years)	Diagnosis of H. pylori infection.
Children (3 to 11 years)	Used when invasive tests (e.g., endoscopy with biopsy) are not feasible, results are inconclusive, or to evaluate the success of eradication therapy.
Pregnant or Lactating Patients	The test is not expected to cause harm and can be used during pregnancy or while breastfeeding.

---

Who Should Not Use the Test

Contraindications relate to conditions that may interfere with the test mechanism and lead to unreliable results. These include:

• Patients with documented or suspected gastric infection other than H. pylori, or atrophic gastritis (chronic stomach inflammation causing lining breakdown), as these conditions may interfere with the urea breath test.
• There is insufficient data to recommend its use for patients who have undergone a gastrectomy (surgical stomach removal).

Important Considerations for Accuracy

For a reliable test outcome, certain medications that suppress H. pylori must be stopped prior to the test:

• Antibiotics and other systemic antibacterial therapies: Must be discontinued for at least four weeks.
• Acid-reducing medications (e.g., Proton Pump Inhibitors, H2-receptor antagonists): Must be discontinued for at least two weeks.

Interactions with other medicines and products

Helicobacter Test Infai is a diagnostic test, and its accuracy is affected by medicinal products that interfere with the underlying biological mechanism: the activity of the Helicobacter pylori bacterium or its urease enzyme. Suppression of H. pylori may lead to false negative results in the test.

Documented Interacting Categories

The primary interacting classes require mandatory withdrawal periods to ensure reliable test results:

• Systemic Antibacterial Therapy: All treatments used against bacterial infections, particularly those targeting H. pylori (eradication therapy), must be discontinued for a minimum of four weeks before the test.
• Acid Antisecretory Agents: Medicines that reduce the secretion of stomach acid, such as proton pump inhibitors (PPIs) and H2-receptor blockers, must be stopped for at least two weeks prior to the test. These agents can suppress the bacterium.

Procedural Interaction Constraints

The required spacing of at least four weeks after systemic antibacterial therapy and two weeks after acid antisecretory agents is a clinically significant regulatory requirement. The test must not be used in patients with documented or suspected gastric infection or atrophic gastritis, as these conditions can also interfere with the urea breath test's result.

The mechanism of Helicobacter Test INFAI relies on a targeted, enzyme-driven chemical reaction that facilitates the systemic detection of bacterial activity.

Targeted Enzyme Hydrolysis and ^13 CO2 Formation

This process engages the highly specific urease enzyme, which is produced solely by the target bacteria, H. pylori, in the stomach. The active ingredient, ^13 C-Urea, acts as the substrate that the enzyme rapidly cleaves through hydrolysis, resulting in the immediate formation of labeled carbon dioxide ( ^13 CO2) and ammonia. The localized efficiency of this chemical reaction influences the concentration of the gaseous product formed.

---

Systemic Gas Transport and Respiratory Elimination

Following its formation, the ^13 CO2 is readily absorbed from the gastric lining into the blood circulation, initiating the systemic transport phase. The blood carries the labeled gas to the lungs where normal pulmonary gas exchange occurs, leading to the predictable elimination of the ^13 CO2 via the exhaled breath. The resulting physiological effect is a measurable increase in the ^13 CO2 concentration ratio in the expired air, which reflects the active presence of the urease-producing organism.

---

Factors Constraining Urease Activity

The mechanistic output is sensitive to factors that suppress the activity of the target enzyme. The use of agents that reduce bacterial load or inhibit urease, such as certain medications, can mechanistically limit the formation of ^13 CO2, potentially leading to a diminished signal. The efficiency of the hydrolysis reaction is also influenced by the gastric pH environment, as this affects enzyme function.

The Helicobacter Test Infai is a non-invasive ^13 C-urea breath test designed for a single administration to diagnose or confirm the eradication of a Helicobacter pylori infection. It should be administered under appropriate medical supervision. The entire procedure takes approximately 40 minutes and requires specific preparation to ensure accurate results.

Essential Pre-Test Instructions

To prevent false negative results, you must fast for at least six hours before the test, preferably overnight, with no food or drink other than plain water. Additionally, the status of the H. pylori bacteria can be suppressed by certain medications, making cessation periods mandatory:

• Antibiotics: Must be discontinued for at least four weeks before the test.
• Acid Antisecretory Agents (such as Proton Pump Inhibitors (PPIs) and H2-receptor antagonists): Must be stopped for at least two weeks before the test.

Test Procedure Overview

1. Baseline Sample Collection: Two breath samples are collected first to establish a baseline ^13 CO2 concentration. The patient exhales gently into the provided sample containers using a straw.
2. Test Meal: The patient then consumes a test meal, typically 200 ml of 100% orange juice (or a solution of 1 gram of citric acid in 200 ml of water) to delay gastric emptying.
3. Test Solution Ingestion: A solution of 75 mg of ^13 C-urea powder dissolved in water (approx. 30 ml) is prepared and immediately ingested.
4. Post-Dose Sample Collection: Exactly 30 minutes after consuming the ^13 C-urea solution, two final breath samples are collected following the same procedure as the baseline collection.

All collected samples are then sealed, labeled, and sent to a qualified laboratory for analysis. If the ^13 C-urea is broken down into ^13 CO2 in the stomach (indicating the presence of H. pylori), the concentration of labeled carbon dioxide in the final breath samples will be significantly higher than the baseline.

Helicobacter Test Infai: Recent Clinical Evidence

The ^13C-urea breath test (UBT), of which Helicobacter Test Infai is a form, is a widely used and validated non-invasive method for the diagnosis of active H. pylori infection in the gastroduodenum. It involves the ingestion of a dose of urea labeled with the non-radioactive isotope carbon-13 (^13C), followed by the collection and analysis of breath samples.

Diagnostic Accuracy and Comparison

Clinical trials and systematic reviews consistently show that the ^13C-UBT is one of the most accurate non-invasive tests available. Its accuracy is generally comparable to, or superior to, invasive methods like the rapid urease test on biopsy samples, and higher than non-invasive serology (blood) tests for detecting active infection.

Diagnostic Performance	Median Sensitivity	Median Specificity
^13C-Urea Breath Test	94%–97%	96%–98%
Stool Antigen Test (SAT)	91%–96%	93%–97%
Serology (Blood Test)	84%–91%	75%–90%

Note: Accuracy figures can vary based on the prevalence of infection in the study population and the specific cut-off values used.

Role in Clinical Practice

The test is utilized both for the initial diagnosis of H. pylori infection and, crucially, for confirming the success of eradication therapy (a 'test-of-cure'). Guidelines recommend waiting at least four weeks after antibiotics and two weeks after certain anti-secretory agents (like Proton Pump Inhibitors) before testing to ensure the accuracy of the result. Clinical evidence supports its use across a broad patient population, including its specialized approval for use in children aged 3 to 11 when invasive tests are inappropriate or inconclusive.

Key Studies & References

1. Systematic review and meta-analysis: Accuracy of the 13C-urea breath test for H. pylori detection in adults: a systematic review and meta-analysis.
2. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) guidelines for the management of H. pylori in children and adolescents

Common questions about Helicobacter Test Infai (FAQ)

Q: How long do I have to wait before drinking water after taking the test capsule?

A: According to the official product information for Helicobacter Test Infai, you should wait for at least 30 minutes after taking the test capsule before you drink any water. This waiting period is indicated in the official instructions to ensure reliable test performance.

Q: Is the test capsule for Helicobacter Test Infai safe for pregnant women?

A: Regulatory documents state that Helicobacter Test Infai can be used by pregnant women. Official information indicates that the test is deemed suitable for use during this period.

Q: Can I use the Helicobacter Test Infai while breastfeeding?

A: Official product information states that the Helicobacter Test Infai is generally considered safe for use while breastfeeding. Its use is indicated as not interfering with the breastfeeding process.

Q: Is Helicobacter Test Infai suitable for use in children?

A: Official product information indicates that Helicobacter Test Infai can be used in children and adolescents. If using the test for very young children, special instructions for collecting the breath samples may apply, which are detailed in the full instructions.

️ Proper Storage

Helicobacter Test Infai should be stored at room temperature, generally defined as 15 C to 25 C (59 F to 77 F). Keep the test kit out of the reach of children and pets. Ensure it remains in the original packaging, protected from moisture and excessive heat.

---

️ Safe Disposal

Do not dispose of this medical product in household trash or wastewater (e.g., toilet or sink). Disposal must follow local regulations and guidelines for pharmaceutical waste. Consult your pharmacist or healthcare provider for information on community take-back programs or designated disposal sites. This helps protect the environment from potential contamination.